Antithrombin-Iii Transfusion in Disseminated Intravascular Coagulation

Schipper, H.G.; Kahlé, L.H.; Jenkins, CharlesS.P; Cate, J. W. Ten

doi:10.1016/s0140-6736(78)90196-4

Cited by 107 publications

(35 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We interpret our data as evidence for the potential therapeu tic value of infusions of AT III activated by heparin in the supportive care of patients with DIC. This conclusion is in agreement with similar findings in more severe cases [5,15]. We suggest that for optimal effec tiveness AT III plasma levels higher than 100% might be necessary.…”

Section: Discussionsupporting

confidence: 92%

“…Conversely, diffuse intravascular clotting (DIC) may lead to decreased AT III levels, presumably due to increased daring of AT III thrombin complexes [4], The therapeutic value of AT III substitution in hereditary and acquired deficiencies has been investigated by several authors [5,11], In general, the AT III con centrate was 'activated' in vitro by the addi tion of a small amount of heparin. As a re sult of this treatment a decrease of the fibri nogen turnover was observed in several cases of DIC [15]. Most of these reports dealt with life-threatening situations where the evaluation of therapeutic measures was complicated by the multitude of other drugs [5,15].…”

Section: Introductionmentioning

confidence: 99%

“…As a re sult of this treatment a decrease of the fibri nogen turnover was observed in several cases of DIC [15]. Most of these reports dealt with life-threatening situations where the evaluation of therapeutic measures was complicated by the multitude of other drugs [5,15]. We had the opportunity of investi gating the effect of AT III infusion on the evolution of a stable DIC syndrome of un known origin.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation

Haak¹,

Stolk²,

Gratama

et al. 1982

Acta Haematol

View full text Add to dashboard Cite

A case report is presented of a 39-year-old woman suffering from a myelodysplastic syndrome, who developed a moderately severe stable diffuse intravascular coagulation (DIC) during an uneventful pregnancy. Intravenous administration of antithrombin III concentrate was attempted to combat the DIC. Improved survival of platelet transfusions, facilitating supportive care, suggested some therapeutic benefit. In contrast, only minimal effects on the results of the coagulation tests were observed.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation

Haak¹,

Stolk²,

Gratama

et al. 1982

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Recently some high-purity AT III concen trates were developed and have been suc cessfully used in DIC in combination with heparin [4][5][6].…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of Antithrombin III Concentrate (BI 6.013) for Disseminated Intravascular Coagulation in Obstetrics

Maki

Terao

Ikenoue

et al. 1987

Gynecol Obstet Invest

View full text Add to dashboard Cite

Antithrombin III (AT III) is known to be the most important inhibitor of serine protease in the coagulation system. In the presence of heparin, AT III is converted from its progressive activity state to an immediate activity state. In disseminated intravascular coagulation (DIC) in the field of obstetrics, the treatment has to be initiated very early. Heparin treatment, on the other hand, is critical since frequently postpartal or postoperative wound bleeding is present. We, therefore, established diagnostic criteria for the early diagnosis of DIC and investigated the clinical efficacy of a therapy with AT III in a well-controlled comparative study versus the injectable synthetic protease inhibitor FOY®. The results of the trial showed that the AT III group (92%; n = 24) was signifiacantly (p < 0.001) superior in clinical efficacy to the FOY group (60%; n = 15). No side effects whatsoever were observed after treatment with AT III concentrate (Behring Institute). From these results, it could be concluded that a single therapy with AT III concentrate can sufficiently control the symptoms of DIC in the filed of obstetrics without the risk of increased bleeding.

show abstract

“…0degard et al (14) employed factor Xa, BZ-Ile-Glu-Gly-Arg-pNA (S 2222) and a Gemsaec centrifugal analyzer. Schipper et al (8) performed their At-III assay with thrombin, chromozym TH and a Vitatron enzyme analyzer.…”

Section: Introductionmentioning

confidence: 99%

Automated Two-Stage Assay for Determination of Antithrombin III with a Centrifugal Analyzer

Andreasen¹

1980

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

The thrombin-inactivating α₂-globulin, antithrombin III (At-III), was measured in plasma and urine with a chromogenic tripeptide substrate, using a centrifugal analyzer. Plasma At-III was subnormal in liver disease. In acute myocardial infarction a mean At-III of approximately 120% of normal was found. At-III in persons who developed deep-vein thrombosis decreased significantly (p < 0.05) between the day of admission and the 3rd day after admission to hospital. Urine from normals did not contain detectable At-III. With increasing urinary albumin increasing concentration of At-III was found.

show abstract

Antithrombin-Iii Transfusion in Disseminated Intravascular Coagulation

Cited by 107 publications

References 9 publications

Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation

Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation

Clinical Evaluation of Antithrombin III Concentrate (BI 6.013) for Disseminated Intravascular Coagulation in Obstetrics

Automated Two-Stage Assay for Determination of Antithrombin III with a Centrifugal Analyzer

Contact Info

Product

Resources

About